Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Saad Z. Usmani, Hang Quach, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja C. Weisel, Xiaomei Shu, Chuang Li, Meletios A. Dimopoulos
Publikováno v:
Blood Advances.
CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib, daratumumab, and dexamethasone (KdD) versus carfilzomib and dexamethasone (Kd) in adults with relapsed/refectory multiple myeloma (RRMM) with 1-3 prior therapies.
Autor:
Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, marcos DeLima, Shahrukh Hashmi, Mohamed A Kharfan-Dabaja, Navneet S Majhail, Rahul Banerjee, Ayman Saad, Gerhard C. Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J. Lekakis, Sagar S. Patel, Hemant S. Murthy, Yago Nieto, Christopher S Strouse, Sherif M. Badawy, Samer AI Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H Vesole, Cindy H Lee, Attaphol Pawarode, Usama Gergis, Kevin Charles Miller, Leona A Holmberg, Aimaz Afrough, Melhem M Solh, Pashna Munshi, Taiga Nishihori, Larry D. Anderson, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H Qazilbash, Nina Shah, Shaji K Kumar, Saad Z. Usmani
Publikováno v:
Blood Advances.
The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell t